Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Woe!! Its the MJ deal of the century!!
$PAOG
THE MJ DEAL OF THE CENTURY $PAOG is taking place now!!
How the heck did I end up here? Oh well, may as well take a look...
Expanding GOOD!! yum Yum!! $INTK
The next 2 quarters will prove very interesting and well deserved for all who waited patiently for their results. imo
$XGEN starting afternoon move right now!! RM coming...OCM predicts approx. 0.50 to 0.70)...
$XGEN$XGEN starting to make a move right now RM coming > got this from OCM currently in iHub j. Thanks OCMillionaire !! (He predicts approx $.50 to $.70)
Or whales testing the pps?...I turned my head for just a little and it was up and back down to almost where it was very quickly...looks like this will spring up and stay up soon enough. Got this suggestion from OCM in ihub j. Tried to visit, but they blocked the entrance.
I didn't know that Tom Sawyer resigned on September!! "Tom Sawyer hereby resigns as Co - Chief Financial Officer (CFO), Vice President, Treasurer, and board member." https://mobile.twitter.com/paogroup?lang=en
Hey, I'm gonna miss that guy!
This keeps building a higher and higher base. $CVLB
Excellent!!
It certainly looks that way...74s then 77s
on deck at the moment...(subject to change) $CVLB
Buying on the dip...$CVLB
What a great stock! We know this is eventually going to multiple dollars
Not sure if it's institutions yet because of somewhat low volume trades, but I did alert Momo's Breakout Board and BBs Stock Haven - twice the other day about the great news when it was about ($0.39-0.41), so some more peeps know about CVLB anyway.
I'm surprised too...when I post, it does not help the board even though try hard to stay very positive. What a surprize - great close! 0.74! (I think we are better off - staying off the radar from the manipulators)
RED ALERT!! Scotty! Beam them out of there now! Scotty: Aye, Captain! But I can't beam them up if they won't sell...I can't get a fix on them. lol Red Alert Sound below >>
I dedicate this song to this "wonderful" stock: STOP! "You Can't Touch This"
And also says the Periodic Table of Elements...lol
LMAO!!
WOW!! This is incredible stervc! lol
Don't worry zonebone, I'll be back; I just can't afford the hit like you all and my Stop Loss kicked in. I think almost 60 cents a share loss is a good reason to leave, but I probably will be back again. I think it is a good stock, sorry for posting on this board. When I come back I promise I won't bother posting here for SURE!! (just hope I can remember my promise). So happy I did not front load and my losses were minimal...lol GLTY
Weak hands here for sure; I had to sell (some) too before because this pps was getting a bit too nasty...will rebuild on the rebound - too many other stocks making money...I may keep some shares but not posting on this board again...later! The future may not be here like I thought. lol
Almost starting a new base here in the 50's. Its a (2) for $1 Special! $CVLB Picked some more up yesterday and today...
Well la de freaking da!
$CVLB OS= 66.1M (eTrade); float =34M (iHub)
TELEMEDICINE NEWS OUT!! $CVLB
2020 Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+
Conversion Labs Reports Preliminary Q2
8:44 AM ET 7/7/20 | GlobeNewswire
Conversion Labs Reports Preliminary Q2 2020 Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+
NEW YORK, July 07, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported preliminary unaudited results for its second quarter ended June 30, 2020. Revenues totaled approximately $9.2 million, up 114% sequentially and up 241% from the same year-ago quarter.
"These record results were driven by strong customer acquisitions and growth in subscription revenue generated by our expanding portfolio of telemedicine, online pharmacy, and wellness brands," said CEO of Conversion Labs, Justin Schreiber.
Conversion Labs CFO, Juan Manuel Piñeiro Dagnery, commented: "This acceleration in top line performance is supporting a significant expansion of our gross margins across our business segments, and demonstrates the strong leverage in our business model. In fact, gross margins for our brands are the strongest they have ever been.
"We continue to see a record number of customers on subscription plans, which is an important metric for our business and indicates a high level of customer satisfaction with our brands. We believe our growing customer retention and lifetime value validates the robustness of our brands and growth strategy."
A major consumer shift to eCommerce and telemedicine during the COVID-19 pandemic has also been supporting the company's rapid growth. The adoption of telemedicine across the healthcare industry has "shifted into hyper-drive" with virtual health care visits on pace to top 1 billion by year end, according to Forrester Research. Another recent report sees the global telemedicine market expanding at a 19.3% compounded annual growth rate, reaching $175 billion by 2026.
Conversion Labs' new cloud-based, end-to-end telemedicine platform, Veritas MD, is supporting the company in addressing this fast growing market with its expanding lineup of telehealth brands. Veritas MD is designed to provide greater access and convenience to the growing number of customers seeking medical treatment and prescription medications from the comfort of their home.
As a result of the company's growth in the first half of the year, management is increasing its full-year 2020 revenue outlook from $36 million to more than $40 million. This compares to revenues of $12.5 million in 2019 and represents growth of more than 220%.
The company expects to report full Q2 results in the second week of August.
About Conversion Labs
Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company's brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.
Important Cautions Regarding Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may, " "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Trademarks are the property of their respective owners.
Company Contact
Conversion Labs
Juan Manuel Piñeiro Dagnery
CFO
Email Contact
Media and Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact
> Dow Jones Newswires
July 07, 2020 08:44 ET (12:44 GMT)
PLEASE READ THE IMPORTANT DISCLOSURES BELOW.
Unless stated otherwise, the web content provided by the E*TRADE family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by E*TRADE Securities LLC or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by E*TRADE Securities LLC or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.
E*TRADE may make available links to other, third party sites or electronic services providers. The material is also being provided to you for educational purposes only unless stated otherwise. The content has been written by a third party not affiliated with E*TRADE or any of its affiliates. E*TRADE and its affiliates are not responsible for the content and the content neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy, sell, or hold any securities.
E*TRADE does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Quotes and other information supplied by independent providers identified on the E*TRADE vendor disclosures page
Statement of Financial Condition | About Asset Protection | Customer/User Agreement | Privacy Statement | Business Continuity Plan | Online Security | Contact Us | About Us | About Our Ads
Securities and futures products and services offered by E*TRADE Securities LLC, Member FINRA/SIPC/NFA. Investment advisory services are offered through E*TRADE Capital Management, LLC, a Registered Investment Adviser. Banking products and services are offered by E*TRADE Bank, a Federal savings bank, Member FDIC, or its subsidiaries. E*TRADE Securities LLC, E*TRADE Capital Management, LLC and E*TRADE Bank are separated but affiliated companies.
System response and account access times may vary due to a variety of factors, including trading volumes, market conditions, system performance, and other factors.
© 2020 E*TRADE Financial Corporation
Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+ust bought some more $CVLB Telemedicine is the latest phenomenon that's only going to be accepted by more doctors since this b*llsh!t COVID-19 and COVID-20 that these geniuses already have said is coming.
NEWS!! $CVLB Conversion Labs Reports Preliminary Q2 2020 Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+
8:44 AM ET 7/7/20 | GlobeNewswire
Conversion Labs Reports Preliminary Q2 2020 Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+
NEW YORK, July 07, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported preliminary unaudited results for its second quarter ended June 30, 2020. Revenues totaled approximately $9.2 million, up 114% sequentially and up 241% from the same year-ago quarter.
"These record results were driven by strong customer acquisitions and growth in subscription revenue generated by our expanding portfolio of telemedicine, online pharmacy, and wellness brands," said CEO of Conversion Labs, Justin Schreiber.
Conversion Labs CFO, Juan Manuel Piñeiro Dagnery, commented: "This acceleration in top line performance is supporting a significant expansion of our gross margins across our business segments, and demonstrates the strong leverage in our business model. In fact, gross margins for our brands are the strongest they have ever been.
"We continue to see a record number of customers on subscription plans, which is an important metric for our business and indicates a high level of customer satisfaction with our brands. We believe our growing customer retention and lifetime value validates the robustness of our brands and growth strategy."
A major consumer shift to eCommerce and telemedicine during the COVID-19 pandemic has also been supporting the company's rapid growth. The adoption of telemedicine across the healthcare industry has "shifted into hyper-drive" with virtual health care visits on pace to top 1 billion by year end, according to Forrester Research. Another recent report sees the global telemedicine market expanding at a 19.3% compounded annual growth rate, reaching $175 billion by 2026.
Conversion Labs' new cloud-based, end-to-end telemedicine platform, Veritas MD, is supporting the company in addressing this fast growing market with its expanding lineup of telehealth brands. Veritas MD is designed to provide greater access and convenience to the growing number of customers seeking medical treatment and prescription medications from the comfort of their home.
As a result of the company's growth in the first half of the year, management is increasing its full-year 2020 revenue outlook from $36 million to more than $40 million. This compares to revenues of $12.5 million in 2019 and represents growth of more than 220%.
The company expects to report full Q2 results in the second week of August.
About Conversion Labs
Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company's brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.
Important Cautions Regarding Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may, " "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Trademarks are the property of their respective owners.
Company Contact
Conversion Labs
Juan Manuel Piñeiro Dagnery
CFO
Email Contact
Media and Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact
> Dow Jones Newswires
July 07, 2020 08:44 ET (12:44 GMT)
PLEASE READ THE IMPORTANT DISCLOSURES BELOW.
Unless stated otherwise, the web content provided by the E*TRADE family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by E*TRADE Securities LLC or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by E*TRADE Securities LLC or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.
E*TRADE may make available links to other, third party sites or electronic services providers. The material is also being provided to you for educational purposes only unless stated otherwise. The content has been written by a third party not affiliated with E*TRADE or any of its affiliates. E*TRADE and its affiliates are not responsible for the content and the content neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy, sell, or hold any securities.
E*TRADE does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Quotes and other information supplied by independent providers identified on the E*TRADE vendor disclosures page
Statement of Financial Condition | About Asset Protection | Customer/User Agreement | Privacy Statement | Business Continuity Plan | Online Security | Contact Us | About Us | About Our Ads
Securities and futures products and services offered by E*TRADE Securities LLC, Member FINRA/SIPC/NFA. Investment advisory services are offered through E*TRADE Capital Management, LLC, a Registered Investment Adviser. Banking products and services are offered by E*TRADE Bank, a Federal savings bank, Member FDIC, or its subsidiaries. E*TRADE Securities LLC, E*TRADE Capital Management, LLC and E*TRADE Bank are separated but affiliated companies.
System response and account access times may vary due to a variety of factors, including trading volumes, market conditions, system performance, and other factors.
© 2020 E*TRADE Financial Corporation
NEWS!! $CVLB Conversion Labs Reports Preliminary Q2 2020 Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+
8:44 AM ET 7/7/20 | GlobeNewswire
Conversion Labs Reports Preliminary Q2 2020 Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+
NEW YORK, July 07, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported preliminary unaudited results for its second quarter ended June 30, 2020. Revenues totaled approximately $9.2 million, up 114% sequentially and up 241% from the same year-ago quarter.
"These record results were driven by strong customer acquisitions and growth in subscription revenue generated by our expanding portfolio of telemedicine, online pharmacy, and wellness brands," said CEO of Conversion Labs, Justin Schreiber.
Conversion Labs CFO, Juan Manuel Piñeiro Dagnery, commented: "This acceleration in top line performance is supporting a significant expansion of our gross margins across our business segments, and demonstrates the strong leverage in our business model. In fact, gross margins for our brands are the strongest they have ever been.
"We continue to see a record number of customers on subscription plans, which is an important metric for our business and indicates a high level of customer satisfaction with our brands. We believe our growing customer retention and lifetime value validates the robustness of our brands and growth strategy."
A major consumer shift to eCommerce and telemedicine during the COVID-19 pandemic has also been supporting the company's rapid growth. The adoption of telemedicine across the healthcare industry has "shifted into hyper-drive" with virtual health care visits on pace to top 1 billion by year end, according to Forrester Research. Another recent report sees the global telemedicine market expanding at a 19.3% compounded annual growth rate, reaching $175 billion by 2026.
Conversion Labs' new cloud-based, end-to-end telemedicine platform, Veritas MD, is supporting the company in addressing this fast growing market with its expanding lineup of telehealth brands. Veritas MD is designed to provide greater access and convenience to the growing number of customers seeking medical treatment and prescription medications from the comfort of their home.
As a result of the company's growth in the first half of the year, management is increasing its full-year 2020 revenue outlook from $36 million to more than $40 million. This compares to revenues of $12.5 million in 2019 and represents growth of more than 220%.
The company expects to report full Q2 results in the second week of August.
About Conversion Labs
Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company's brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.
Important Cautions Regarding Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may, " "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Trademarks are the property of their respective owners.
Company Contact
Conversion Labs
Juan Manuel Piñeiro Dagnery
CFO
Email Contact
Media and Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact
> Dow Jones Newswires
July 07, 2020 08:44 ET (12:44 GMT)
PLEASE READ THE IMPORTANT DISCLOSURES BELOW.
Unless stated otherwise, the web content provided by the E*TRADE family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by E*TRADE Securities LLC or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by E*TRADE Securities LLC or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.
E*TRADE may make available links to other, third party sites or electronic services providers. The material is also being provided to you for educational purposes only unless stated otherwise. The content has been written by a third party not affiliated with E*TRADE or any of its affiliates. E*TRADE and its affiliates are not responsible for the content and the content neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy, sell, or hold any securities.
E*TRADE does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Quotes and other information supplied by independent providers identified on the E*TRADE vendor disclosures page
Statement of Financial Condition | About Asset Protection | Customer/User Agreement | Privacy Statement | Business Continuity Plan | Online Security | Contact Us | About Us | About Our Ads
Securities and futures products and services offered by E*TRADE Securities LLC, Member FINRA/SIPC/NFA. Investment advisory services are offered through E*TRADE Capital Management, LLC, a Registered Investment Adviser. Banking products and services are offered by E*TRADE Bank, a Federal savings bank, Member FDIC, or its subsidiaries. E*TRADE Securities LLC, E*TRADE Capital Management, LLC and E*TRADE Bank are separated but affiliated companies.
System response and account access times may vary due to a variety of factors, including trading volumes, market conditions, system performance, and other factors.
© 2020 E*TRADE Financial Corporation
$QUBT is way undervalued! OS here is only 7.9M shares (according to eTrade), and the float is about 750k only. In the right hands and news this could explode much further - even into Mega green. imo
QUANTUM COMPUTING stock $QUBT keep on your radar; very promising...the future is at hand. OS= 7.9M; float = about 750k Nice SS
QUANTUM COMPUTING stock $QUBT keep on your radar; very promising...
Nice post! The future is here with Quantum Computing. $QUBT
TELEHEALTH stock $CVLB One of the NEXT big businesses coming down the pike because of this b*llsh!t COVID-19. The doctor now tells you what's going on without even seeing you in person! It's like virtual freaking healthcare, but it's taking off!! $CVLB revenues are up 60% and growing by leaps and bounds...good price to get in...(around $0.39-0.41 a share). Only 66M issued shares (according to Etrade) with a 34M float..They just had a run, retracing and accumulating for the next run, so don't miss out. I mean, it even has CV for COVID in its ticker! GLTY
That's a good catch. I could have sworn I heard the rattling of a snake as I was reading that SURG statement. lol
Thanks for the warning bUrRpPPP!
TELEHEALTH stock $CVLB One of the next big businesses coming down the pike because of this b*llsh!t COVID-19. The doctor now tells you what's going on without even seeing you in person! Its like virtual healthcare, but it's taking off!!$CVLD revenues are up 60% and growing by leaps and bounds...good price to get in...(around $0.39 a share). Only 71M issued shares with a 34M float.. GLTY
I agree, but you have to admit - this pps is kinda funny, knowing all the business they are generating ..patience here is key but wearing thin, like the volume. Q3 and Q4 positive results are definitely coming.(They also need a really good PR to get this where it's supposed to be...not just a tweet).
I want to thank all the weak hands for your continued cheap shares...(Just goes to show you, not many peeps really seem to believe in quantum computing);
You are correct. My bad. Please have mod delete my other post! Seriously! One of these boards p*ssed me off and I thought it was this board, but now I believe I have made a mistake.